Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Sales and Divestitures (2024 - 2025)

Janux Therapeutics (JANX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $15588.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 523.52% to $15588.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $15588.0, a 523.52% increase, with the full-year FY2025 number at $15588.0, up 523.52% from a year prior.
  • Gains from Sales and Divestitures was $15588.0 for Q4 2025 at Janux Therapeutics, up from $10275.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $15588.0 in Q4 2025 to a low of $2500.0 in Q3 2024.